摘要:
The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof.
摘要翻译:本申请描述了式I或II的新型异恶唑啉或其药学上可接受的盐或前药形式,其中A,R 1,R 2,R 3, R 4,Z 4,U,X,Y,Z a,以及n在本说明书中定义,其可用作基质金属蛋白酶抑制剂( MMP),TNF-α转化酶(TACE)或其组合。
摘要:
The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP) and/or TNF-α converting enzyme (TACE), or a combination thereof.